Been there, done that, again and again with Dengue. Tetravalent vaccines crash and burn in expanded trials where larger numbers of subjects reveal hidden issues. Novartis had a great candidate a few years back that went all the way to advanced Phase 3 and 30k test subjects before they found that it was killing a small percentage, and causing significant side effects in larger numbers than early clinical work had indicated.
News 
Market Data 
Discover 
AI
